Moneycontrol
    Moneycontrol PRO
    LAMF
    LAMF

    Pharma Industry

    Jump to

    • Three-day pharma industry event from Nov 25 to host global pharma leaders, exhibitors, investors

      Organised by Informa Markets in India, the 18th edition of CPHI and PMEC India 2025 will feature the complete pharmaceutical value chain under one roof and focus on key industry themes such as API self-reliance, sustainability, digitalization, and exports, the organisers said in a statement.

    • Eli Lilly to invest over $1 billion in India to expand manufacturing capacity

      The company, which launched its blockbuster weight-loss drug Mounjaro in India this year, currently does not operate its own manufacturing facility in the country

    • India bulk drug makers start preparing for Ozempic patent expiry

      Drugmakers in India — the world’s largest supplier of non-patented medicines — aim to tap what could be a $94 billion global opportunity by 2035

    • Pharma products face stricter scrutiny over drug brand name confusion: Report

      Brands with similar or identical names will be prohibited from being marketed. Drug manufacturers will soon be required to upload detailed formulation information alongside their brand names to a government portal.

    • Budget wish list: Pharma industry seeks tax benefits, effective intellectual property rights regime

      Outlining the sector's wish list for the upcoming Union Budget, Organisation of Pharmaceutical Producers of India (OPPI) Director General Anil Matai urged the government to explore methods to incentivise R&D investments, such as deductions on R&D expenses, research-linked incentives for MNCs, and corporate tax concessions.

    • Entero IPO: Should investors pop the flotation pill?

      The company will have to scale up its top line manifold to be able to protect its profitability

    • Cipla: Sailing well on the US pharma business front

      The company’s chronic portfolio continues to gain strength and the US base business has moved to a new orbit. This is supportive for medium-term earnings growth, which makes us constructive on the business.

    • Hetero to invest Rs 1,000 crore in AP over two years to expand pharma business

    • Pharma sector gets first tranche of payment under under PLI scheme

    • India’s pharma industry’s problems need to be fixed, now!

    • Research crucial for Indian pharma industry to move from ‘volume’ to ‘value’: Mansukh Mandaviya

    • Govt wants to ease compliance burden on pharma industry: Mansukh Mandaviya

    • Indian pharma industry estimated to grow 9-11% in 2021-22: ICRA

    • Mansukh Mandaviya urges pharma industry to make India a manufacturing hub

    • Veterans Unpacked | D.S. Brar: "Your network is your net worth, and your credibility is your currency"

    • Gland Pharma’s focus on injectables yields superior growth

    • I am sure global pharma industry will support India's WTO proposal of IP waiver for COVID-19: Piyush Goyal

    • Indian pharma firms go local seeking to end reliance on China

    • Budget 2021 could be the vaccine for the pharmaceutical industry

    • Coronavirus pandemic | Centre to expedite clearances to bulk drug projects to fight COVID-19

    • 3-Point Analysis | API export restriction: Takeaways for pharma industry

    • Indian pharma industry likely to grow at 10-13% in FY'21: ICRA

    • Editor's Take | Budget 2020: The pharma industry's wishlist

    • NPPA issues notices to Lupin, Ranbaxy, others for selling FDCs without price approval

    • Pharma: Here's what all happened in the sector last week

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347